The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma

被引：0
|
作者：
Derenzini, Enrico [1 ]
Lemoine, Manuela [1 ]
Brighenti, Elisa [2 ]
Davis, Richard Eric [1 ]
Zinzani, Pier Luigi [3 ]
Younes, Anas [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Bologna, Dept Radiol & Histocytopathol Clin Sci, Bologna, Italy
[3] Univ Bologna, Dept Hematol Oncol L&A Seragnoli, Bologna, Italy
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1175 / 1175
页数：1
相关论文
共 42 条
  • [1] Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
    Koppikar, Priya
    Abdel-Wahab, Omar
    Hedvat, Cyrus
    Marubayashi, Sachie
    Patel, Jay
    Goel, Aviva
    Kucine, Nicole
    Gardner, Jeffrey R.
    Combs, Andrew P.
    Vaddi, Kris
    Haley, Patrick J.
    Burn, Timothy C.
    Rupar, Mark
    Bromberg, Jacqueline F.
    Heaney, Mark L.
    de Stanchina, Elisa
    Fridman, Jordan S.
    Levine, Ross L.
    BLOOD, 2010, 115 (14) : 2919 - 2927
  • [2] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Mesa, Ruben A.
    Pardanani, Animesh D.
    Cortes-Franco, Jorge
    Thomas, Deborah A.
    Estrov, Zeev
    Fridman, Jordan S.
    Bradley, Edward C.
    Erickson-Viitanen, Susan
    Vaddi, Kris
    Levy, Richard
    Tefferi, Ayalew
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127
  • [3] INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
    Li, Jun
    Favata, Margaret
    Kelley, Jennifer A.
    Caulder, Eian
    Thomas, Beth
    Wen, Xiaoming
    Sparks, Richard B.
    Arvanitis, Ari
    Rogers, James D.
    Combs, Andrew P.
    Vaddi, Kris
    Solomon, Kimberly A.
    Scherle, Peggy
    Newton, Robert
    Fridman, Jordan S.
    NEOPLASIA, 2010, 12 (01): : 28 - 38
  • [4] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
    Rodgers, James D.
    Fridman, Jordan S.
    Shepard, S.
    Maduskuie, T. P.
    Arvanitis, A. G.
    Wang, H.
    Shao, L.
    Folmer, B.
    Falahatpisheh, N.
    Rafalski, M.
    Storace, L.
    Jalluri, R. K.
    Vaddi, K.
    Haley, P. J.
    Burn, T. C.
    Rupar, M.
    Liu, P. C.
    Covington, M. B.
    Caulder, E.
    Li, J.
    Waeltz, P.
    Margulis, A.
    Wynn, R.
    Becker-Pasha, M.
    Li, Y.
    Lo, Y.
    Thomas, B.
    Hollis, G.
    Favata, M. F.
    Wen, X.
    Kelly, J.
    Solomon, K.
    Scherle, P. A.
    Shi, J.
    Yeleswaram, S.
    Newton, R. C.
    Friedman, S. M.
    Metcalf, B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [5] A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
    Van den Neste, Eric
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne S.
    Bailly, Sarah
    Knoops, Laurent
    Morschhauser, Franck
    HAEMATOLOGICA, 2018, 103 (05) : 840 - 848
  • [6] Activity Of a JAK1/JAK2 Inhibitor In a Patient With KIT-Mutated Systemic Mastocytosis (SM) Associated With Myelofibrosis
    Santos, Fabio P. S.
    Helman, Ricardo
    Pereira, Welbert O.
    Puga, Renato D.
    Nakashima, Sandra S.
    Bello, Isabel C.
    Diniz, Michelli S.
    Hamerschlak, Nelson
    Campregher, Paulo Vidal
    BLOOD, 2013, 122 (21)
  • [7] A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter
    Levy, Richard
    Bradley, Edward C.
    Schacter, Lee
    Garrett, William M.
    Vaddi, Kris
    Contel, Nancy
    Rumi, Elisa
    Gattoni, Elisabetta
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro
    BLOOD, 2009, 114 (22) : 132 - 132
  • [8] Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    Levy, Richard
    Bradley, Edward
    Garrett, William
    Vaddi, Kris
    Contel, Nancy
    Sandor, Victor
    Huber, Reid Michael
    Schacter, Lee P.
    Rumi, Elisa
    Gattoni, Elisabetta
    Antonioli, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2010, 116 (21) : 142 - 143
  • [9] INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia
    Passamonti, Francesco
    Rumi, Elisa
    Della Porta, Matteo G.
    Portolan, Monica
    Elena, Chiara
    Arcaini, Luca
    Pascutto, Cristiana
    Vanelli, Laura
    Vaddi, Kris
    Lazzarino, Mario
    Cazzola, Mario
    BLOOD, 2009, 114 (22) : 1135 - 1135
  • [10] RUXOLITINIB, A JAK1/JAK2 INHIBITOR, INHIBITS CELL PROLIFERATION AND INDUCES APOPTOSIS IN HODGKIN LYMPHOMA (HL) AND PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL)
    Yin, C.
    Ayello, J.
    Van de Ven, C.
    Lee, S.
    Cairo, M. S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 154 - 154
12345